Modalis Therapeutics Corporation (TYO:4883)

Market Cap	4.03B -28.0%
Revenue (ttm)	n/a
Net Income	-1.82B
EPS	-22.39
Shares Out	89.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,943,900
Open	44.00
Previous Close	43.00
Day's Range	44.00 - 49.00
52-Week Range	43.00 - 119.00
Beta	0.36
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About Modalis Therapeutics

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM an epigenome editing technology that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorpor...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 17
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4883